📣 VC round data is live. Check it out!

SynBiotic Valuation Multiples

Discover revenue and EBITDA valuation multiples for SynBiotic and similar public comparables like The Cannabist Company, HYTN Innovations, Humanoid Global Holdings, iAnthus Capital Holdings and more.

SynBiotic Overview

About SynBiotic

SynBiotic SE is engaged in the development of Phyto-cannabinoids and other herbal compounds concentrated molecules as well as the development of wellness products. The company engages in synthetic production, drug development, cannabinoids, dietary supplements and cosmetic products. Geographical presence in Germany, Austria, UK, Switzerland and Other countries. Majority of its revenue comes from domestic market.


Founded

2015

HQ

Germany

Employees

103

Financials (FY)

Revenue: $17M
EBITDA: ($2M)

EV

$20M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

SynBiotic Financials

SynBiotic reported last fiscal year revenue of $17M and negative EBITDA of ($2M).

In the same fiscal year, SynBiotic generated $6M in gross profit, ($2M) in EBITDA losses, and had net loss of ($11M).

Revenue (LTM)


SynBiotic P&L

In the most recent fiscal year, SynBiotic reported revenue of $17M and EBITDA of ($2M).

SynBiotic is unprofitable as of last fiscal year, with gross margin of 34%, EBITDA margin of (14%), and net margin of (68%).

See analyst estimates for SynBiotic
Last FY20232024202620272028
Revenue$17M$4M$17M
Gross Profit$6M$2M$6M
Gross Margin34%39%34%
EBITDA($2M)($8M)($2M)
EBITDA Margin(14%)(184%)(14%)
EBIT Margin(74%)(285%)(74%)
Net Profit($11M)($12M)($11M)
Net Margin(68%)(275%)(68%)
Net Debt$5M--

Financial data powered by Morningstar, Inc.

SynBiotic Stock Performance

SynBiotic has current market cap of $16M, and enterprise value of $20M.

Market Cap Evolution


SynBiotic's stock price is $2.10.

SynBiotic share price increased by 6.9% in the last 30 days, and decreased by 32.9% in the last year.

SynBiotic has an EPS (earnings per share) of $-1.48.

See more trading valuation data for SynBiotic
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$20M$16M7.3%6.9%-25.5%-32.9%$-1.48

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

SynBiotic Valuation Multiples

SynBiotic trades at 1.2x EV/Revenue multiple, and (8.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for SynBiotic

EV / Revenue (LTM)


SynBiotic Financial Valuation Multiples

As of May 30, 2026, SynBiotic has market cap of $16M and EV of $20M.

SynBiotic has a P/E ratio of (1.4x).

Last FY20232024202620272028
EV/Revenue1.2x4.3x1.2x
EV/EBITDA(8.3x)(2.4x)(8.3x)
EV/EBIT(1.6x)(1.5x)(1.6x)
EV/Gross Profit3.5x11.1x3.5x
P/E(1.4x)(1.3x)(1.4x)
EV/FCF(23.1x)(5.7x)(23.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified SynBiotic Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

SynBiotic Margins & Growth Rates

In the most recent fiscal year, SynBiotic reported gross margin of 34%, EBITDA margin of (14%), and net margin of (68%).

See estimated margins and future growth rates for SynBiotic

SynBiotic Margins

Last FY2024202720282029
Gross Margin34%34%
EBITDA Margin(14%)(14%)
EBIT Margin(74%)(74%)
Net Margin(68%)(68%)
FCF Margin(5%)(5%)

SynBiotic Growth Rates

23/2426/2727/2828/29
Revenue Growth270%
Gross Profit Growth223%
EBITDA Growth(72%)
EBIT Growth(4%)
Net Profit Growth(9%)
FCF Growth(75%)

Data powered by FactSet, Inc. and Morningstar, Inc.

SynBiotic Operational KPIs

SynBiotic's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for SynBiotic
Last FY20232024202620272028
Revenue per Employee$0.2M--
Opex per Employee$0.2M--
S&M Expenses to Revenue5%14%5%
G&A Expenses to Revenue8%23%8%
Opex to Revenue108%324%108%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

SynBiotic Competitors

SynBiotic competitors include The Cannabist Company, HYTN Innovations, Humanoid Global Holdings, iAnthus Capital Holdings, Pineapple, Weed, Dogecoin Cash, Aion Therapeutic, Ayr Wellness and MariMed.

Most SynBiotic public comparables operate across Cannabis, CannaTech and ViceTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
The Cannabist Company----
HYTN Innovations12.4x-(18.0x)-
Humanoid Global Holdings755.3x-(4.8x)-
iAnthus Capital Holdings----
Pineapple----
Weed----
Dogecoin Cash----
Aion Therapeutic14.4x-(0.9x)-

This data is available for Pro users. Sign up to see all SynBiotic competitors and their valuation data.

Start Free Trial

SynBiotic M&A Activity

SynBiotic has acquired 2 companies to date.

Last acquisition by SynBiotic was on November 14th 2024. SynBiotic acquired WEECO Pharma for $13M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by SynBiotic

WEECO Pharma
Ilesol Pharmaceuticals
Description
WEECO Pharma wholesales and imports medical cannabis products across Europe. The Berlin-based firm supplies raw materials, finished goods, and related services to pharmacies and clinics. It handles regulatory-compliant distribution for therapeutic cannabis applications.
Ilesol Pharmaceuticals is a Danish manufacturer of white-label CBD and CBG oils, capsules, and cosmetics compliant with EU novel food regulations. Its production facility in Denmark supplies bulk extracts and finished products to brands in Europe and North America.
HQ CountryGermanyCroatia
HQ City
Hildesheim
Varaždin
Deal Date14 Nov 202419 Apr 2024
Valuation$13Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all SynBiotic acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About SynBiotic

When was SynBiotic founded?SynBiotic was founded in 2015.
Where is SynBiotic headquartered?SynBiotic is headquartered in Germany.
How many employees does SynBiotic have?As of today, SynBiotic has over 103 employees.
Is SynBiotic publicly listed?Yes, SynBiotic is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of SynBiotic?SynBiotic trades under SBX ticker.
When did SynBiotic go public?SynBiotic went public in 2021.
Who are competitors of SynBiotic?SynBiotic main competitors include The Cannabist Company, HYTN Innovations, Humanoid Global Holdings, iAnthus Capital Holdings, Pineapple, Weed, Dogecoin Cash, Aion Therapeutic, Ayr Wellness, MariMed.
What is the current market cap of SynBiotic?SynBiotic's current market cap is $16M.
What is the current revenue of SynBiotic?SynBiotic's last fiscal year revenue is $17M.
What is the current EV/Revenue multiple of SynBiotic?Current revenue multiple of SynBiotic is 1.2x.
Is SynBiotic profitable?No, SynBiotic is not profitable.
How many companies SynBiotic has acquired to date?As of May 2026, SynBiotic has acquired 2 companies.
What was the largest acquisition by SynBiotic?$13M acquisition of WEECO Pharma on 14th November 2024 was the largest M&A SynBiotic has done to date.
What companies SynBiotic acquired?SynBiotic acquired WEECO Pharma and Ilesol Pharmaceuticals.
In how many companies SynBiotic has invested to date?SynBiotic hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to SynBiotic

Lists including SynBiotic

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial